2-[4-(2-quinolinylmethoxy)phenoxy]ethanol methanesulfonate(ester) | 1100420-29-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 2-[4-(2-quinolinylmethoxy)phenoxy]ethanol methanesulfonate(ester)
• 英文别名: 2-[4-(Quinolin-2-ylmethoxy)phenoxy]ethyl methanesulfonate
• CAS: 1100420-29-8
• 化学式: C₁₉H₁₉NO₅S
• 分子量: 373.43
• InChiKey: ALWMUKPTEITREM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  26
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  83.1
• 氢给体数：
  0
• 氢受体数：
  6

文献信息

• [EN] FUSED IMIDAZOLE DERIVATIVES AS MULTIDRUG RESISTANCE MODULATORS<br/>[FR] DERIVES FUSIONNES D'IMIDAZOLE EN TANT QUE MODULATEURS DE LA RESISTANCE A DES MEDICAMENTS MULTIPLES
  申请人：JANSSEN PHARMACEUTICA N.V.

  公开号：WO1997034897A1

  公开（公告）日：1997-09-25

  (EN) This invention concerns the compounds of formula (I), the $i(N)-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein the dotted line is an optional bond; n is 1 or 2; R1 is hydrogen; halo; formyl; C1-4alkyl optionally substituted with hydroxy, C1-4alkyloxy, C1-4alkylcarbonyloxy, imidazolyl, thiazolyl or oxazolyl; or a radical of formula -X-COOR5, -X-CONR6R7 or -X-COR10 wherein -X- is a direct bond, C1-4alkanediyl or C2-6alkenediyl; R5 is hydrogen, C1-12alkyl, Ar, Het, C1-6alkyl substituted with C1-4alkyloxy, aryl or heteroaryl; R6 and R7 each independently are hydrogen or C1-4alkyl; R2 is hydrogen, halo, C1-4alkyl, hydroxyC1-4alkyl, C1-4alkyloxycarbonyl, carboxyl, formyl or phenyl; R3 is hydrogen, C1-4alkyl or C1-4alkyloxy; R4 is hydrogen, halo, C1-4alkyl, C1-4alkyloxy or haloC1-4alkyl; Z is -CH2-, -CH2-CH2-, -CH=CH-, -CHOH-CH2-, -O-CH2-, -C(=O)-CH2- or -C(=NOH)-CH2-; -A-B- is a bivalent radical; A1 is a direct bond, optionally substituted C1-6alkanediyl, C1-6alkanediyl-oxy-C1-6alkanediyl, carbonyl, C1-6alkanediylcarbonyl, optionally substituted C1-6alkanediyloxy; A2 is a direct bond or C1-6alkanediyl; and Q is aryl. Processes for preparing said products, formulations comprising said products and their use as a medicine are disclosed, in particular for inhibiting or reversing the effects of multidrug resistance.(FR) L'invention concerne les composés représentés par la formule (I), leurs formes de N-oxydes, leurs sels d'apport acceptables sur le plan pharmaceutique et leurs formes isomères sur le plan stéréochimique, la ligne pointillée constituant une liaison éventuelle; n est 1 ou 2; R1 représente hydrogène, halo, formyle; alkyle C1-C4 éventuellement substitué par hydroxy, alkyloxy C1-C4, alkylcarbonyloxy C1-C4, imidazolyle, thiazolyle ou oxazolyle; ou un radical représenté par la formule -X-COOR5, -X-CONR6R7 ou -X-COR10 dans laquelle -X- représente une liaison directe, alcanediyle C1-C4 ou alcènediyle C2-C6; R5 représente hydrogène, alkyle C1-C12, Ar, Het, alkyle C1-C6 substitué par alkyloxy C1-4, aryle ou hétéroaryle; R6 et R7 représentent, indépendamment l'un de l'autre, hydrogène, halo, alkyle C1-4, hydroxyalkyl C1-4, alkyloxy C1-C4 carbonyle, carboxyle, formyle ou phényle; R3 représente hydrogène, alkyle C1-C4 ou alkyloxy C1-C4; R4 représente hydrogène, halo, alkyle C1-C4, alkyloxy C1-C4 ou haloalkyle C1-C4; Z représente -CH2-, -CH2-CH2-, -CH=CH-, -CHOH-CH2-, -O-CH2-, -C(=O)-CH2- ou -C(=NOH)-CH2-; -A-B- représente un radical bivalent; A1 représente une liaison directe, alcanediyle C1-C6 éventuellement substitué, alcanediyle-C1-C6-oxy-alcanediyle-C1-C6, carbonyle, alcanediyle C1-C6 carbonyle, alcanediyloxy C1-C6 éventuellement substitué; A2 représente une liaison directe ou alcanediyle C1-C6; Q représente aryle. Procédés de préparation desdits produits, formulations comprenant lesdits produits, ainsi que leur utilisation en tant que médicament, en particulier dans le but d'inhiber ou d'inverser les effets de la résistance à des médicaments multiples.

  该发明涉及公式（I）的化合物，其$i(N)-氧化物形式，药学上可接受的加成盐和立体化学异构体形式，其中虚线是可选键；n为1或2；R1为氢；卤素；甲酰基；C1-4烷基，可选用羟基，C1-4烷氧基，C1-4烷基羧酸酯基，咪唑基，噻唑基或异噁唑基；或公式-X-COOR5，-X-CONR6R7或-X-COR10的基团，其中-X-是直接键，C1-4烷二基或C2-6烯二基；R5为氢，C1-12烷基，Ar，Het，C1-6烷基，取代为C1-4烷氧基，芳基或杂环芳基；R6和R7各自独立地为氢或C1-4烷基；R2为氢，卤素，C1-4烷基，羟基C1-4烷基，C1-4烷氧羰基，羧基，甲酰基或苯基；R3为氢，C1-4烷基或C1-4烷氧基；R4为氢，卤素，C1-4烷基，C1-4烷氧基或卤素C1-4烷基；Z为-CH2-，- - -，-CH=CH-，-CHOH- -，-O- -，-C（=O）- -或-C（=NOH）- -；-A-B-为二价基团；A1为直接键，可选用C1-6烷二基，C1-6烷二基氧-C1-6烷二基，羰基，C1-6烷二基羧酸酯基，可选用C1-6烷二氧基；A2为直接键或C1-6烷二基；Q为芳基。公开了制备所述产品的过程，包含所述产品的制剂及其作为药物的用途，特别是用于抑制或逆转多药耐药的效果。
• Fused imidazole derivatives as multidrug resistance modulators
  申请人：——

  公开号：US20030087895A1

  公开（公告）日：2003-05-08

  This invention concerns the compounds of formula 1 the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein the dotted line is an optional bond; n is 1 or 2; R 1 is hydrogen; halo; formyl; C 1-4 alkyl optionally substituted with hydroxy, C 1-4 alkyloxy, C 1-4 alkylcarbonyloxy, imidazolyl, thiazolyl or oxazolyl; or a radical of formula —X—COOR 5 , —X—CONR 6 R 7 or —X—COR 10 wherein —X— is a direct bond, C 1-4 alkanediyl or C 2-6 alkenediyl; R 5 is hydrogen, C 1-12 alkyl, Ar, Het, C 1-6 alkyl substituted with C 1-4 alkyloxy, aryl or heteroaryl; R 6 and R 7 each independently are hydrogen or C 1-4 alkyl; R 2 is hydrogen, halo, C 1-4 alkyl, hydroxyC 1-4 alkyl, C 1-4 alkyloxycarbonyl, carboxyl, formyl or phenyl; R 3 is hydrogen, C 1-4 alkyl or C 1-4 alkyloxy; R 4 is hydrogen, halo, C 1-4 alkyl, C 1-4 alkyloxy or haloC 1-4 alkyl; Z is —CH 2 —, —CH 2 —CH 2 —, —CH═CH—, —CHOH—CH 2 —, —O—CH 2 —, —C(═O)—CH 2 — or —C(═NOH)—CH 2 —; —A—B— is a bivalent radical; A 1 is a direct bond, optionally substituted C 1-6 alkanediyl, C 1-6 alkanediyl-oxy-C 1-6 alkanediyl, carbonyl, C 1-6 alkanediylcarbonyl, optionally substituted C 1-6 alkanediyloxy; A 2 is a direct bond or C 1-6 alkanediyl; and Q is aryl. Processes for preparing said products, formulations comprising said products and their use as a medicine are disclosed, in particular for inhibiting or reversing the effects of multidrug resistance.

  本发明涉及公式1的化合物，其N-氧化物形式，药学上可接受的加成盐和立体化学异构体形式，其中虚线是可选键；n为1或2；R1为氢；卤素；甲酰基；C1-4烷基，可选地被羟基，C1-4烷氧基，C1-4烷基羰酰氧基，咪唑基，噻唑基或氧唑基取代；或式的基团-X-COOR5，-X-CONR6R7或-X-COR10，其中-X-是直接键，C1-4烷二基或C2-6烯二基；R5为氢，C1-12烷基，Ar，Het，C1-6烷基取代的C1-4烷氧基，芳基或杂环芳基；R6和R7各自独立地为氢或C1-4烷基；R2为氢，卤素，C1-4烷基，羟基C1-4烷基，C1-4烷氧基羰基，羧基，甲酰基或苯基；R3为氢，C1-4烷基或C1-4烷氧基；R4为氢，卤素，C1-4烷基，C1-4烷氧基或卤素C1-4烷基；Z为-CH2-，- - -，-CH═CH-，-CHOH- -，-O- -，-C(═O)- -或-C(═NOH)- -；-A-B-是双价基团；A1是直接键，可选地取代的C1-6烷二基，C1-6烷二氧-C1-6烷二基，羰基，C1-6烷二基羰基，可选地取代的C1-6烷二氧基；A2是直接键或C1-6烷二基；Q为芳基。公开了制备上述产品的方法，包括上述产品的配方和它们作为药物的用途，特别是用于抑制或逆转多药耐受的效果。
• FUSED IMIDAZOLE DERIVATIVES AS MULTIDRUG RESISTANCE MODULATORS
  申请人：JANSSEN PHARMACEUTICA N.V.

  公开号：EP0888352A1

  公开（公告）日：1999-01-07
• FUSED IMIDAZOLE DERIVATIVES FOR IMPROVING ORAL BIOAVAILABILITY OF PHARMACEUTICAL AGENTS
  申请人：JANSSEN PHARMACEUTICA N.V.

  公开号：EP1011726A2

  公开（公告）日：2000-06-28
• US6218381B1
  申请人：——

  公开号：US6218381B1

  公开（公告）日：2001-04-17